Disposition of 615 shares by Albers Jeffrey W. of Kymera Therapeutics at .0746 subject to Rule 16b-3
| KYMR Stock | USD 40.82 0.03 0.07% |
Slightly above 102 percent of Kymera Therapeutics' retail investors are aggressively looking to sell. The analysis of the overall investor sentiment regarding Kymera Therapeutics suggests that quite a large number of traders are panicking. Kymera Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Kymera Therapeutics. Many technical investors use Kymera Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Kymera |
Filed transaction by Kymera Therapeutics Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Kymera Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Kymera Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Kymera Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Kymera Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kymera Therapeutics Fundamental Analysis
We analyze Kymera Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kymera Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kymera Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Kymera Therapeutics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Kymera Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kymera Therapeutics stock to make a market-neutral strategy. Peer analysis of Kymera Therapeutics could also be used in its relative valuation, which is a method of valuing Kymera Therapeutics by comparing valuation metrics with similar companies.
Peers
Kymera Therapeutics Related Equities
| MLYS | Mineralys Therapeutics, | 6.14 | ||||
| CGEM | Cullinan Oncology | 3.37 | ||||
| FHTX | Foghorn Therapeutics | 1.83 | ||||
| RVMD | Revolution Medicines | 1.05 | ||||
| STTK | Shattuck Labs | 0.91 | ||||
| EWTX | Edgewise Therapeutics | 1.20 | ||||
| GLUE | Monte Rosa | 1.26 | ||||
| NRIX | Nurix Therapeutics | 2.05 | ||||
| AGIO | Agios Pharm | 3.28 | ||||
| PRLD | Prelude Therapeutics | 4.03 | ||||
| CCCC | C4 Therapeutics | 4.68 | ||||
| IPSC | Century Therapeutics | 7.27 |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.